Raleigh Inceptor Bio Start-Up Acquires Florida Production Plant

RALEIGH – Inceptor Bio continues to rapidly advance its oncology product portfolio, acquiring a production facility in Florida. A team of on-site employees will also be part of the Inceptor Bio team.

Financial terms of the agreement for the acquisition of the 29,000 square feet GMP [good manufacturing practice] Arranta Bio plant have not been disclosed. Some Arranta workers at the Gainesville, Fla. Site will join Inceptor, the company said.

Inceptor recently closed with $ 26 million in funding and has a management team built around gene editing technology.

The site will be used to produce material for clinical trials, Inceptor said.

Leaders of Inceptor Bio include Mike Nicholson, Ph.D., and Chris Heery, MD, both of whom helped develop the gene-editing platform and CAR-T therapies at Durham-based Precision Biosciences. . Dave Ousterout, Ph.D., co-founder of Morrisville’s Locus Biosciences, is Scientific Director. In addition, Inceptor Bio Founder and CEO Shailesh Maingi founded Kineticos Life Sciences, a Raleigh-based consulting firm for life science companies.

The $ 26 million investment came from the Kineticos Disruptor Fund.

“We are delighted to welcome the experienced and talented Arranta operations team and look forward to establishing GMP clinical cell therapy manufacturing as a key strategic capability. This acquisition accelerates Inceptor Bio’s journey to the clinic for our CAR-T, CAR-M and CAR-NK programs with our lead candidate CAR-T slated for IND in early 2023, ”said Maingi.

Previous Caravan of hundreds of migrants heads north through Mexico
Next Local business industries suffer since pandemic, strive to recruit younger population